This is a contrast between Cronos Group Inc. (NASDAQ:CRON) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) based on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cronos Group Inc.||N/A||0.00||N/A||-0.03||0.00|
|Adverum Biotechnologies Inc.||1.40M||293.09||69.92M||-1.04||0.00|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 represents Cronos Group Inc. (NASDAQ:CRON) and Adverum Biotechnologies Inc. (NASDAQ:ADVM)’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Cronos Group Inc.||0.00%||0%||0%|
|Adverum Biotechnologies Inc.||-4,994.29%||-32.7%||-30.8%|
The table shown features the ratings and recommendations for Cronos Group Inc. and Adverum Biotechnologies Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Cronos Group Inc.||2||1||0||2.33|
|Adverum Biotechnologies Inc.||0||0||0||0.00|
Cronos Group Inc. has a 18.81% upside potential and a consensus price target of $18.
Institutional and Insider Ownership
Institutional investors owned 17.34% of Cronos Group Inc. shares and 74.3% of Adverum Biotechnologies Inc. shares. Insiders owned roughly 5.15% of Cronos Group Inc.’s shares. On the other hand, insiders owned about 6.43% of Adverum Biotechnologies Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Cronos Group Inc.||5.98%||9.04%||146.67%||68.45%||121.47%||106.54%|
|Adverum Biotechnologies Inc.||14.42%||54.72%||33.33%||-19.67%||-26.02%||56.19%|
For the past year Cronos Group Inc. has stronger performance than Adverum Biotechnologies Inc.
Cronos Group Inc. beats Adverum Biotechnologies Inc. on 7 of the 10 factors.
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.
Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.